A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Summary

This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

Timeline

Start

2022-08-31

Primary completion

2024-06-26

Completion

2028-12

Outcome

Met primary endpoint

release “研究表明，在胃肠胰神经内分泌肿瘤患者中，镥[ 177 Lu]氧奥曲肽安全性整体可控，并且与高剂量长效奥曲肽相比，能显著改善PFS。” hengrui.com ↗

Publications

• Liu F, Yang H, Zhang J, Li J, Qiao Y, Chen J, Song S. Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [(1)(7)(7)Lu]Lu-DOTA-TATE. EJNMMI Res. 2026 Feb 25;16(1):52. doi: 10.1186/s13550-026-01402-2.
• Liu F, Li P, Xu J, Zhang J, Xu X, Chen Z, Qiao Y, Liang Y, Chen J, Song S. Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China. EJNMMI Res. 2024 Nov 28;14(1):119. doi: 10.1186/s13550-024-01185-4.

Drugs

Indications